In this week's Chutes & Ladders, Valeant names a CEO, Biogen poaches a Pfizer exec and United Therapeutics shakes up its management.
Shire's liver drug flunks its second test in a year.
Public Citizen sues FDA over experts' CV redactions
Sanofi has teamed up with Duke Clinical Research Institute and Massachusetts General Hospital for a machine learning-enabled drug adherence research project.
Merck KGaA has given Unisys responsibility for handling IT service requests and incidents involving its 48,000 employees in a five-year deal.
Microsoft has ordered 10 million strands of synthetic DNA from Twist Bioscience to support research into the storage of digital data on DNA.
Patrick Soon-Shiong has rigged himself the richest pay package for an executive in the biopharma industry.
Spring Bank Pharma and Oncobiologics become latest biotechs to file discounted IPOs.
Alizé Pharma is preparing to advance the development of its treatment for Prader-Willi syndrome after the drug AZP-531 came through a Phase II study.
Intellia has set out to prove that gene editing pioneers are immune to the current market chill for biotech IPOs.